[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]
Antiviral Res. 2019 Jan 3. pii: S0166-3542(18)30407-8. doi: 10.1016/j.antiviral.2018.12.020. [Epub ahead of print]
The efficacy of poly-ICLC against Ebola-Zaire virus (EZV) infection in mice and cynomolgus monkeys.
Kende M1, Paragas J2, Salazar AM3.
Author information: 1 United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD, 21702, United States. Electronic address: email@example.com. 2 United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD, 21702, United States. 3 Oncovir, Inc., 3203 Cleveland Avenue, Washington D.C, 20008, United States.
The potential protection of poly-ICLC (Hiltonol®) a double stranded RNA (dsRNA) against EZV infection was assessed with prophylactic and therapeutic administration to wild type and TLR3-negative mice, and in non-human primates (NHPs) by measuring EZV serum titers, survival extension, and serum liver and kidney function markers. Various doses of aqueous and liposomal poly-ICLC monotherapy provided robust protection in otherwise lethal murine Ebola virus challenge models, when treatment is started on the day of -or one day after virus challenge. There was no advantage of liposomal vs. the aqueous poly-ICLC form. Protection appeared to be independent of TLR-3. NHPs treated with poly-ICLC and challenged with EZV survived longer but eventually succumbed to Ebola infection. Nevertheless, the liver and kidney serum markers were markedly reduced in the infected and treated NHPs. In the two longest surviving poly-ICLC- treated NHPs, the day 10 serum EZV titer was reduced 2.1 and 30 fold respectively.
KEYWORDS: Aqueous/liposomal poly-ICLC; Efficacy in mice; NHP EZV titers; NHP liver/kidney enzymes; NHP survival time; TLR+/ TLR-3 mice
PMID: 30611774 DOI: 10.1016/j.antiviral.2018.12.020
Keywords: Ebola; Antivirals; Animal models.